COMBINATION CYCLOPHOSPHAMIDE, DOXORUBICIN, AND CISPLATIN (CAP) CHEMOTHERAPY FOR EXTENSIVE NON-SMALL CELL CARCINOMAS OF THE LUNG

Abstract

Fifty consecutive patients with extensive non-small cell carcinoma of the lung were randomized to 1 of 2 chemotherapeutic regimens. Twenty-three patients (group 1) received cyclophosphamide (600 mg/m2), doxorubicin (40 mg/m2) and cisplatin (50 mg/m2) every 3 wk; 27 patients (group 2) received cyclophosphamide (600 mg/m2), doxorubicin (40 mg/m2) and cisplatin (100 mg/m2) every 3 wk. The objective response rates were 4% and 7% in groups 1 and 2, respectively. Median survival duration was 15.2 wk (group 1) and 21.7 wk (group 2; P .gtoreq. 0.3). Hematologic toxicity was minimal in group 1 and moderate in group 2. Renal toxicity was moderate in group 2 only. Combination chemotherapy with cyclophosphamide, doxorubicin and cisplatin as used in this study is not superior to previous studies using cyclophosphamide as a single agent.